No Data
No Data
Kanglong Chemical (300759): Overseas front-end R&D demand is picking up, and profit margins are expected to improve quarterly
The 2024Q1 results are in line with our expectations for 2024Q1: revenue of 2,671 billion yuan, -2.0% YoY; net profit to mother of 231 million yuan, -33.8% YoY; operating cash flow 7.46
Kanglong Chemical (300759): New orders are improving, and month-on-month improvements can be expected
Guide to this report: New orders are improving, performance is expected to be repaired quarterly, the integrated transformation logic continues to be implemented, optimistic about the company's long-term growth, and maintaining an increase in holdings rating. Investment Essentials: Maintaining an “Overweight” rating. 2024Q1 Revenue 26.71
Kanglong Chemical (300759): Waiting for the inflection point, the order side shows signs of improvement
Matters: The company announced 24Q1 results, achieving revenue of 2,671 billion yuan (yoy -2.0%) and net profit to mother of 231 million yuan (yoy -33.8%). Exclude one-time losses due to the closure of the Shanghai laboratory, and
Kanglong Chemical (300759): New Q1 orders increased by more than 20% year-on-year, demand for downstream innovation gradually picked up
Incident: On April 25, 2024, Kanglong Chemical released its 2024 quarterly report. The company achieved revenue of 2,671 billion yuan in Q1, a year-on-year decrease of 1.95%; net profit to mother was 231 million yuan, a year-on-year decrease of 33 million yuan.
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%
Pharmaron Beijing Co (HKG:3759) reported a profit attributable to owners of 230.6 million yuan for the quarter ended March 31, 2024, down 33.8% from 348.3 million yuan in the previous year, according
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small molecule CDMO are growing rapidly; 2) the clinical research business is progressing steadily, and the macromolecule and CGT sectors are under pressure in the short term; 3) the increase in customer demand sends a positive signal of recovery, keeping the growth guide unchanged throughout the year. (Mainichi Keizai Shimbun)
No Data